Levi & Korsinsky Investigates Possible Securities Fraud Violations by Arvinas, Inc. (ARVN)
Hello investors! Levi & Korsinsky is looking into potential securities fraud violations by Arvinas, Inc. (ARVN). It seems there may have been some issues with federal securities laws that we’re investigating.
Here’s what happened: Arvinas recently shared in a filing with the U.S. Securities and Exchange Commission that they, along with their partner Pfizer, Inc., made a decision to delay the expected completion date for their Phase 3 trial for the breast cancer therapy vepdegestrant. The completion date moved from November 2024 to January 2025, with top-line data now anticipated in the first quarter of 2025.
As a result of this news, Arvinas’s stock price dropped during intraday trading on the same day. If you want more details, you can check out the link provided in the article or reach out to Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or give them a call at (212)363-7500.
Why choose Levi & Korsinsky? Well, over the past two decades, they’ve become a well-known securities litigation firm that has recovered hundreds of millions of dollars for shareholders. Their team of over 70 staff members specializes in representing investors in complex securities litigation. Levi & Korsinsky has been recognized in ISS Securities Class Action Services’ Top 50 Report for seven consecutive years as one of the top securities litigation firms in the U.S. It’s important to note that past results don’t guarantee similar outcomes.
If you want to get in touch with Levi & Korsinsky, here’s their contact information:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
And remember, Markets Insider and Business Insider Editorial Teams were not part of creating this post. Stay informed and take the necessary steps to protect your investments. Thank you for being a responsible investor!
